Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix said its multiple myeloma minimal residual disease assay measured the primary efficacy endpoint supporting FDA accelerated approval of Bristol Myers Squibb's ZENBEXUS, making the test part of the regulatory foundation for the first approved CELMoD therapy in multiple myeloma.
Hematogenix said its proprietary MM MRD assay was used to measure the primary efficacy endpoint cited in the FDA’s accelerated approval of ZENBEXUS, also known as iberdomide. The announcement was issued from Tinley Park, Illinois, on August 19, 2026, and describes ZENBEXUS as the first approved CELMoD therapy for multiple myeloma.
The direct corporate read-through is to Bristol Myers Squibb, whose drug received the regulatory decision, while Hematogenix is presented as the specialized trial-services and biomarker company supporting the registration. No approval sales forecast, label detail beyond the accelerated-approval designation, or commercial terms between the companies were provided.
The next datapoints are the confirmatory evidence required for the accelerated approval, the timing and scale of the ZENBEXUS launch, and any disclosures from BMY on pricing, uptake, or portfolio impact. The supplied financial snapshot shows BMY with FY2025 revenue of $48.2B, down 0.2% year over year, a 14.6% net margin, and $3.46 diluted EPS, but it does not isolate this therapy’s contribution.
Hematogenix’s assay measured the primary endpoint supporting FDA accelerated approval of Bristol Myers Squibb’s ZENBEXUS (BMY).
The regulatory milestone expands BMY’s marketed oncology portfolio and creates a concrete commercial catalyst, but the supplied figures provide no ZENBEXUS sales estimate or valuation gap to support a larger move. BMY’s $48.2B FY2025 revenue base and 14.6% net margin make the approval strategically positive while leaving the near-term P&L effect modest until uptake is disclosed.
The trade fails if launch demand is weak or confirmatory evidence does not support continued approval, leaving the announcement with little measurable earnings impact.
CoverageSource: PR Newswire · Published here WED, AUG 19 · 8:32 AM ET · the only report in this recordHow this is decided →
PR NEWSWIRE / FILEEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The bull case is that first-mover status as the first approved CELMoD therapy gives BMY a differentiated multiple-myeloma launch platform beyond its existing $48.2B revenue base.
Limited bear case — the announcement supplies no revenue forecast, pricing detail, or confirmatory-trial result, so the approval may not change near-term earnings expectations materially.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →